Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | PARP1 | P09874 | 7/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25175090 | 0.84 | ALOX15 (0.72) | ALOX15HTTPARP1PARP2LMNA | |
| SCHEMBL30503169 | 0.84 | ALOX15 (0.72) | ALOX15HTTPARP1PARP2LMNA | |
| SCHEMBL25169244 | 0.84 | ALOX15 (0.72) | ALOX15HTTPARP1PARP2LMNA | |
| SCHEMBL1865315 | 0.77 | HTT (0.86) | ALOX15HTTPARP1PARP2ALDH1A1 | |
| SCHEMBL833951 | 0.76 | PARP1 (0.78) | ALOX15HTTPARP1PARP2LMNA | |
| SCHEMBL25172566 | 0.76 | ALOX15 (0.61) | ALOX15ALDH1A1MEN1KMT2ABLM | |
| SCHEMBL30503190 | 0.76 | ALOX15 (0.61) | ALOX15ALDH1A1MEN1KMT2ABLM | |
| SCHEMBL29802795 | 0.75 | PARP1 (0.80) | ALOX15HTTPARP1PARP2LMNA | |
| SCHEMBL17207994 | 0.75 | PARP1 (0.80) | ALOX15HTTPARP1PARP2LMNA | |
| SCHEMBL20214403 | 0.74 | HTT (0.58) | ALOX15HTTPARP1PARP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454236-B1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-8877944-B2 | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides as PARP inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-20120245142-A1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-09-27 | — | — | US | disclosed |
| EP-2454236-A1 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011006794-A9 | 3-OXO-2, 3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245142-A1 | 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS | PARP1, PARP2, PARP3 | ALOX15 450/4885HTT 2222/4885PARP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.